TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial
Brief Summary: The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140.


Options:
A: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo
B: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300U/mL, Drug: Non-insulin anti-diabetic treatment | Arm Label: Tresiba; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin degludec, 100 U/mL, Drug: Non-insulin anti-diabetic treatment | Intervention Type: DRUG; Name: Insulin glargine, 300U/mL; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin degludec, 100 U/mL; Assigned to Arm(s): Tresiba | Intervention Type: DRUG; Name: Non-insulin anti-diabetic treatment; Assigned to Arm(s): Toujeo, Tresiba
C: Arm Label: Glargine insulin; Type: EXPERIMENTAL; Interventions: Drug: Glargine insulin | Arm Label: NPH insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin | Intervention Type: DRUG; Name: Glargine insulin; Assigned to Arm(s): Glargine insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): NPH insulin
D: Intervention Type: DRUG; Name: Metformin on top of intensive insulin therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission
Brief Summary: Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine /pyrimethamine plus amodiaquine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Pyrimethamine/sulfadoxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Sulfadoxine/pyrimethamine and artesunate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Brief Summary: Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system.

This is the second trial to utilize a recombinant active form of lysosomal enzyme, glucocerebrosidase, (human prGCD) which is expressed and purified in a bioreactor system from transformed carrot plant root cell line.


Options:
A: Arm Label: 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): 30 units/kg, 60 units/kg
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Taliglucerase alfa 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: Taliglucerase alfa 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): Taliglucerase alfa 30 units/kg, Taliglucerase alfa 60 units/kg
D: Arm Label: prGCD 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Arm Label: prGCD 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 30 Units/kg | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 60 Units/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.
Brief Summary: Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to bone pain and increased risk of fractures. The normal osteoclasts are responsible for bone degradation through stimulation from the malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity but may have serious side-effects due to renal toxicity and the optimal dose have not been established.

In a randomized double blinded design it is aim to compare the standard of monthly injections of 90 mg pamidronate with 30 mg.

The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12 months after starting the treatment in newly diagnosed treatment demanding multiple myeloma. Secondary end-points are skeletal related events, cost-utility analysis, response, response duration and survival and quality of life with respect to fatigue and pain.


Options:
A: Arm Label: Zoledronate acid; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid | Arm Label: No treatment control; Type: OTHER; Interventions: Other: No treatment control | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronate acid | Intervention Type: OTHER; Name: No treatment control; Assigned to Arm(s): No treatment control
B: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
C: Intervention Type: DRUG; Name: pamidronate; Assigned to Arm(s): N/A
D: Arm Label: Arm I: Thal/ZLD; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: zoledronic acid | Arm Label: Arm II: ZLD; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I: Thal/ZLD | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Arm I: Thal/ZLD, Arm II: ZLD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Web-Based Feedback to Improve Blood Pressure Control
Brief Summary: High blood pressure affects 65 million adults in the United States, and more than one third of these individuals do not have adequate control of their blood pressure. Individuals who ask specific questions and discuss important medical issues with their doctors are more likely to receive appropriate medical care than individuals who do not. This study will evaluate the effectiveness of an interactive web site that provides individualized feedback and encourages doctor-patient communication as a way to maintain adequate blood pressure control.


Options:
A: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
B: Arm Label: lifestyle counseling tailored; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored counseling | Arm Label: lifestyle counseling motivational; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored counseling; Assigned to Arm(s): lifestyle counseling tailored | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): lifestyle counseling motivational
C: Arm Label: Intervention Condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Web-Based Intervention | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Web-Based Intervention; Assigned to Arm(s): Intervention Condition
D: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM)
Brief Summary: The purpose of this study is to learn whether or not all children with ear infections (acute otitis media or AOM) should be treated with antibiotics. The study will compare two treatment strategies, "watchful waiting" or treatment with antibiotics, to determine which is more appropriate for children with AOM. About 268 children in Pittsburgh, between the ages of 6-23 months, with AOM will be enrolled in the study. They will be treated either with Augmentin (an antibiotic) or placebo for 10 days and closely followed for about 1 month. Parents will be asked to write information about their child in a Patient Diary. A general physical exam, including an ear exam, will be performed 4 times during the study. A mucus sample will be collected from the back of each child's nose. Parents will be asked questions during phone calls and at every visit. If a child has not improved or has worsened, the investigators will prescribe a different antibiotic that is known to kill resistant germs.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM)
Brief Summary: The purpose of this study is to learn whether or not all children with ear infections (acute otitis media or AOM) should be treated with antibiotics. The study will compare two treatment strategies, "watchful waiting" or treatment with antibiotics, to determine which is more appropriate for children with AOM. About 268 children in Pittsburgh, between the ages of 6-23 months, with AOM will be enrolled in the study. They will be treated either with Augmentin (an antibiotic) or placebo for 10 days and closely followed for about 1 month. Parents will be asked to write information about their child in a Patient Diary. A general physical exam, including an ear exam, will be performed 4 times during the study. A mucus sample will be collected from the back of each child's nose. Parents will be asked questions during phone calls and at every visit. If a child has not improved or has worsened, the investigators will prescribe a different antibiotic that is known to kill resistant germs.


Options:
A: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
B: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormon® Compared to Darbepoetin Alfa.
Brief Summary: This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin alfa (Aranesp) in patients with renal anemia. Eligible patients will be randomized to receive comparable subcutaneous injections of either darbepoetin alfa (30 micrograms) or NeoRecormon (6000IU). They will then be crossed over to the alternative treatment arm for further treatment. After each injection pain will be assessed using the visual analogue scale (VAS) and 6-point verbal rating scale (VRS), and patient preference will be assessed. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
B: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
C: Arm Label: Epoetin Hospira; Type: OTHER; Interventions: Biological: Epoetin Hospira Arm, Drug: IV Iron | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care Arm, Drug: IV Iron | Intervention Type: BIOLOGICAL; Name: Epoetin Hospira Arm; Assigned to Arm(s): Epoetin Hospira | Intervention Type: OTHER; Name: Standard of Care Arm; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Epoetin Hospira, Standard of Care
D: Arm Label: Epoetin Bio-Manguinhos; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa-BioManguinhos | Arm Label: EPO-BioSimilar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa-BioSimilar | Intervention Type: DRUG; Name: Epoetin Alfa-BioManguinhos; Assigned to Arm(s): Epoetin Bio-Manguinhos | Intervention Type: DRUG; Name: Epoetin Alfa-BioSimilar; Assigned to Arm(s): EPO-BioSimilar

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormon® Compared to Darbepoetin Alfa.
Brief Summary: This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin alfa (Aranesp) in patients with renal anemia. Eligible patients will be randomized to receive comparable subcutaneous injections of either darbepoetin alfa (30 micrograms) or NeoRecormon (6000IU). They will then be crossed over to the alternative treatment arm for further treatment. After each injection pain will be assessed using the visual analogue scale (VAS) and 6-point verbal rating scale (VRS), and patient preference will be assessed. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
D: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly

Answer: C